[A25-43] Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Addendum to Project A24-110
Last updated 15.05.2025
Project no.:
A25-43
Commission:
Commission awarded on 25.03.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with International Federation of Gynecology and Obstetrics 2014 Stage III to IVA locally advanced cervical cancer who have not received prior definitive therapy
Unchanged after addendum:
hint of non-quantifiable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-43_en
| Project no. | Title | Status |
|---|---|---|
| A24-110 | Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-05-D15 A G-BA decision was published.